Senseonics Holdings Inc
AMEX:SENS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2831
0.7375
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Senseonics Holdings Inc
Cash Equivalents
Senseonics Holdings Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Senseonics Holdings Inc
AMEX:SENS
|
Cash Equivalents
$73m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash Equivalents
$1.8B
|
CAGR 3-Years
32%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
Senseonics Holdings Inc
Glance View
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.
See Also
What is Senseonics Holdings Inc's Cash Equivalents?
Cash Equivalents
73m
USD
Based on the financial report for Sep 30, 2024, Senseonics Holdings Inc's Cash Equivalents amounts to 73m USD.
What is Senseonics Holdings Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-11%
Over the last year, the Cash Equivalents growth was 31%. The average annual Cash Equivalents growth rates for Senseonics Holdings Inc have been 19% over the past three years , -11% over the past five years .
You don't have any saved screeners yet
